{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:17:19Z","timestamp":1790691439713,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>To systematically evaluate the efficacy and safety of mirabegron compared to \u03b1-adrenergic receptor antagonists for treating distal ureteral stones.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A comprehensive search of EMBASE, PubMed, and Cochrane databases was conducted to identify studies comparing mirabegron and \u03b1-adrenergic receptor antagonists for stone expulsion. The primary outcome was stone expulsion rate (SER), and secondary outcomes included stone expulsion interval (SEI) and pain episode frequency. Risk ratio (RR) and mean differences (MD) with 95% CIs were calculated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six studies involving 487 participants were included. There was no significant difference in SER between mirabegron and \u03b1-adrenergic receptor antagonists (RR = 1.06; 95% CI = 0.93\u20131.22; P = 0.34). SEI showed no significant difference either (MD = 0.05; 95% CI = \u22123.23 to 3.34; P = 0.58). However, pain episodes were significantly reduced in the mirabegron group (MD = \u22120.36; 95% CI = \u22120.63 to \u22120.09; P = 0.01). Subgroup analysis showed reduced pain episodes with mirabegron versus silodosin but not tamsulosin. Mirabegron also had fewer side effects like headache (RR = 0.34; 95% CI = 0.13\u20130.87; P = 0.02) and orthostatic hypotension (RR = 0.11; 95% CI = 0.02\u20130.55; P = 0.008), while dizziness and ejaculation dysfunction rates were comparable.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Mirabegron reduced pain episodes during treatment for distal ureteral stones, particularly when compared to silodosin, despite no significant differences in SER or SEI. Its favorable safety profile suggests potential as a therapeutic option. Further randomized controlled trials are needed to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1517979","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:14:54Z","timestamp":1742368494000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["The efficacy and safety of mirabegron and \u03b1-adrenergic receptor antagonist in the treatment of distal ureteral stones: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yicheng","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengze","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yini","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s11255-023-03880-y","article-title":"Evaluation of the efficacy and safety of either or both mirabegron and silodosin, as a medical expulsive therapy for distal ureteric stones","volume":"56","author":"Abdel-Kader","year":"2024","journal-title":"Int. Urol. Nephrol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.4111\/kju.2010.51.3.193","article-title":"Tamsulosin versus alfuzosin in the treatment of patients with distal ureteral stones: prospective, randomized, comparative study","volume":"51","author":"Ahmed","year":"2010","journal-title":"Korean J. Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1007\/s11255-019-02368-y","article-title":"Efficacy of silodosin or mirabegron in medical expulsive therapy for ureteral stones: a prospective, randomized-controlled study","volume":"52","author":"Bayar","year":"2020","journal-title":"Int. Urol. Nephrol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1345\/aph.1G586","article-title":"Pharmacologic expulsive treatment of ureteral calculi","volume":"40","author":"Beach","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"B5","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1089\/end.2023.0266","article-title":"Nonopioid pain management pathways for stone disease","volume":"38","author":"Cabo","year":"2024","journal-title":"J. Endourol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s11255-013-0509-9","article-title":"The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials","volume":"46","author":"Cui","year":"2014","journal-title":"Int. Urol. Nephrol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.euf.2024.12.004","article-title":"Reply to: Rong Dai and Changkai Deng's Letter to the Editor re: Anirban Dey, Georgios Georgiadis, Justin Umezurike, et al. Mirabegron Versus Placebo and Other Therapeutic Modalities in the Treatment of Patients with Overactive Bladder Syndrome-A Systematic Review. Eur Urol Focus. In press","author":"Dey","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"B8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.5173\/ceju.2023.182","article-title":"Comparing silodosin and mirabegron as medical expulsive therapy for distal ureteral calculus: a prospective, randomised study","volume":"77","author":"Faridi","year":"2024","journal-title":"Cent. Eur. J. Urol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"key":"B10","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1442-2042.2011.02810.x","article-title":"Efficacy of selective \u03b11A adrenoceptor antagonist silodosin in the medical expulsive therapy for ureteral stones","volume":"18","author":"Itoh","year":"2011","journal-title":"Int. J. Urol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2174\/1389450118666170120165554","article-title":"\u03b23-Adrenoceptor control of lower genitourinary tract organs and function in male: an overview","volume":"19","author":"Kaya","year":"2018","journal-title":"Curr. Drug Targets"},{"key":"B12","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.eururo.2018.03.020","article-title":"Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis","volume":"74","author":"Kelleher","year":"2018","journal-title":"Eur. Urol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11934-009-0007-x","article-title":"Medical therapy of stone disease: from prevention to promotion of passage options","volume":"10","author":"Lipkin","year":"2009","journal-title":"Curr. Urol. Rep."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1159\/000521171","article-title":"Efficacy of mirabegron as medical expulsive therapy for distal ureteral stones: a prospective, randomized, double-blinded, controlled study","volume":"106","author":"Morsy","year":"2022","journal-title":"Urol. Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1097\/MOU.0000000000000849","article-title":"Modern surgical strategies in the management of complex ureteral strictures","volume":"31","author":"Paffenholz","year":"2021","journal-title":"Curr. Opin. Urol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst. Rev."},{"key":"B17","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.euf.2017.04.001","article-title":"Burden of urolithiasis: trends in prevalence, treatments, and costs","volume":"3","author":"Raheem","year":"2017","journal-title":"Eur. Urol. Focus"},{"key":"B18","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1177\/03915603231204081","article-title":"Does mirabegron have a potential role as a medical expulsive therapy in the treatment of distal ureteral stones? A prospective randomized controlled study","volume":"91","author":"Samir","year":"2024","journal-title":"Urologia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0022-5347(01)64173-9","article-title":"Ureteral stones clinical guidelines panel summary report on the management of ureteral calculi. The American urological association","volume":"158","author":"Segura","year":"1997","journal-title":"J. Urol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"S370","DOI":"10.1016\/s0302-2838(21)00646-1","article-title":"Mirabegron, tamsulosin monotherapy versus combination in treatment of distal ureteric stone. A randomized controlled clinical trial","volume":"79","author":"Seleem","year":"2021","journal-title":"Eur. Urol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s11255-017-1667-y","article-title":"Expression of \u03b2-adrenergic receptor subtypes in human normal and dilated ureter","volume":"49","author":"Shen","year":"2017","journal-title":"Int. Urol. Nephrol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s00240-018-1075-5","article-title":"Efficacy of mirabegron in medical expulsive therapy","volume":"47","author":"Solakhan","year":"2019","journal-title":"Urolithiasis"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1280487","DOI":"10.3389\/fmed.2023.1280487","article-title":"Mirabegron for medical expulsive therapy of ureteral stones: a systematic review and meta-analysis","volume":"10","author":"Song","year":"2023","journal-title":"Front. Med. (Lausanne)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"4465","DOI":"10.1007\/s00345-021-03772-9","article-title":"Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study","volume":"39","author":"Tang","year":"2021","journal-title":"World J. Urol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.1097\/01.ASN.0000146012.44570.20","article-title":"Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up","volume":"15","author":"Taylor","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/s41581-020-0320-7","article-title":"Determining the true burden of kidney stone disease","volume":"16","author":"Thongprayoon","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ejphar.2007.06.056","article-title":"Expressions and mechanical functions of alpha1-adrenoceptor subtypes in hamster ureter","volume":"573","author":"Tomiyama","year":"2007","journal-title":"Eur. J. Pharmacol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.eururo.2015.07.040","article-title":"EAU guidelines on diagnosis and conservative management of urolithiasis","volume":"69","author":"T\u00fcrk","year":"2016","journal-title":"Eur. Urol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.urology.2015.06.030","article-title":"Medical expulsive therapy for ureteric colic: new hard evidence: commentary on: medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial","volume":"86","author":"Van Asseldonk","year":"2015","journal-title":"Urology"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1097\/01.ju.0000133557.39515.b6","article-title":"Pharmacological characterization of beta-adrenoceptor subtypes mediating relaxation in porcine isolated ureteral smooth muscle","volume":"172","author":"Wanajo","year":"2004","journal-title":"J. Urol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/j.1464-410X.2010.09801.x","article-title":"A multicentre, prospective, randomized trial: comparative efficacy of tamsulosin and nifedipine in medical expulsive therapy for distal ureteric stones with renal colic","volume":"108","author":"Ye","year":"2011","journal-title":"BJU Int."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1517979\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:14:59Z","timestamp":1742368499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1517979\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":31,"alternative-id":["10.3389\/fphar.2025.1517979"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1517979","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,19]]},"article-number":"1517979"}}